Mary Kerr (NeRRe)
After selling its spinout to Bayer in a $875M-plus deal, NeRRe Therapeutics grabs $28M for some 'unfinished business'
Some biotech CEOs find themselves out of jobs following a buyout. Not Mary Kerr.
In fact, after Bayer dished out $425 million in cash to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
